1 month retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide for the treatment of

More than 13% of patients on that dose also experienced an upper respiratory tract infection, a contagious illness affecting the nose, sinuses and throat

However, as we embark on a weight management journey, it's crucial to consider the long-term efficacy and sustainability of these treatments

Wegovy, another Novo Nordisk drug with semaglutide, is prescribed to help obese people lose weight and to reduce the risk of major cardiovascular events in obese or overweight adults with known heart disease

The aggressive titration tail in the 12 mg arm of the Phase 2 trial was strongly associated with higher rates of transient gastrointestinal adverse events, which is why researchers generally favor slower escalation when tolerability is prioritized